Published online Jun 20, 2024. doi: 10.5662/wjm.v14.i2.89284
Peer-review started: October 26, 2023
First decision: November 30, 2023
Revised: January 8, 2024
Accepted: February 26, 2024
Article in press: February 26, 2024
Published online: June 20, 2024
Processing time: 231 Days and 20.1 Hours
Electronic cigarettes (ECs) have been promoted as alternatives to traditional cigarettes.
To investigate ECs’ effects on respiratory system, especially in patients with respiratory diseases.
We randomly selected 25 smokers with stable moderate asthma and matched them with 25 healthy smokers. All were subjucted to pulmonary function tests (PFTs), impulse oscillometry (IOS), fraction exhaled Nitric Oxide (FeNO), exhaled breathe condensate (EBC) and biomarker measurements before and after vaping one nicotine-containing EC.
The increase in FeNO 30 minutes after EC, reflecting airway inflammation, significantly correlated with increase of residual volume (RV), total lung capacity, respiratory impedance at 5 Hz (Z5Hz) and respiratory resistance at 5 and 20 Hz (R5Hz and R20Hz). No significant correlations were found between EBC biomarkers' changes and respiratory mechanics.
This is the first study demonstrating that the changes in airway inflammation caused by EC have direct effects in respiratory mechanics of asthmatic patients.
Core Tip: This is the first study that correlates the acute changes in pulmonary function and in airway inflammation in patients with asthma after vaping one electronic cigarette.
- Citation: Kotoulas SC, Domvri K, Tsantos A, Papagiouvanni I, Michailidou A, Spyratos DG, Porpodis K, Grigoriou I, Papakosta D, Pataka A. Is there a correlation between the changes in airway inflammation and the changes in respiratory mechanics after vaping in patients with asthma? World J Methodol 2024; 14(2): 89284
- URL: https://www.wjgnet.com/2222-0682/full/v14/i2/89284.htm
- DOI: https://dx.doi.org/10.5662/wjm.v14.i2.89284
Electronic cigarette (EC) is a novel smoking product promoted to replace tobacco cigarette in smokers' daily habits. However, despite the fact that the effects of the tobacco cigarette have been investigated thoroughly the last decades, this is not the case for EC. There is evidence that EC have several acute effects on lung function of healthy individuals[1-6], and on lung function and airway inflammation of patients with asthma[4-6] and chronic obstructive pulmonary disease (COPD)[6,7]. In a previous study, we have evaluated the acute effects of EC on lung function and airway inflammation in patients with asthma compared to healthy individuals[4]. However, we did not evaluate the possible correlations of the changes on airway inflammation with the acute effects of EC on lung function.
With this study we investigate the correlations between the changes in airway inflammation, reflected by the changes in fraction exhaled Nitric Oxide (FeNO) and exhaled breathe condensate (EBC) biomarkers, with the changes in pulmonary function tests (PFTs) and impulse oscillometry after vaping one nicotine-containing EC.
The protocol of this study was approved by the Ethics Committee of the Medical School, Aristotle University of Thessaloniki, reference 369-8/22.2.2017, before the initiation of enrolment and all participants gave their written informed consent. The protocol of the study was also registered in ISRCTN-registry (ISRCTN89151172).
The participants in this study[4] were divided into two groups: (1) The “asthmatic group” which consisted of asthmatic patients with moderate persistent stable asthma well controlled by receiving “step 3” treatment according to global initiative for asthma (GINA) guidelines[8]; and (2) the “control group” which consisted of healthy individuals. The participants of both groups were current every day smokers[9]. Exclusion criteria for the asthmatic group were: (1) Age under 18 years; (2) an acute asthma exacerbation the last month before enrollment; (3) a change in the asthma medication the last month before enrollment; and (4) another acute or chronic disease apart from asthma the last two weeks before enrollment. Out of 87 eligible patients, 25 were recruited by using a random number generator. Exclusion criteria for the control group were: (1) Age under 18 years; and (2) the existence of any acute or chronic disease the last two weeks before enrollment. The recruitment of the 25 participants of the control group was made after matching them with those of the asthmatic group for gender, age, body mass index and smoking history (number of packyears).
All participants were subjected to PFTs (spirometry, static lung volumes and Diffusion Lung Capacity for Carbon Monoxide)[10], total respiratory resistances measurement with an impulse oscillometry system (IOS)[11], FeNO measurement[12] and EBC gathering[13] for measurement of pH[13] and of concentrations of Interleukins 1b, 4, 5, 6, 8, 10, 13 and 17A and tumor necrosis factor-alpha with flow cytometry and of concentrations of 8-Isoprostane and leukotriene B4 with enzyme-linked immunosorbent assay[13]. Subsequently, participants vaped an EC, which had the same concentration of nicotine in the cartridge (medium nicotine content) and was of the same company. The composition of the e-liquid had been analyzed in a previous study[1]. Participants of both groups vaped the EC for five minutes (10 puffs with 30-second intervals between puffs). A new cartridge and atomiser were used for every participant. During EC inhalation two asthmatic patients presented mild cough and wheezing, which resolved automatically after a few minutes without necessitate reliever medication usage. Fifteen minutes after vaping the participants were subjected again to PFTs and IOS measurements and 30 min after vaping they were subjected to a new FeNO measurement and EBC gathering.
Statistical analysis was performed using the SPSS software. All variables were continuous. To investigate for correlations between the changes in airway inflammation and the changes in respiratory mechanics linear regression was used between the difference in FeNO and in EBC biomarkers and the difference in PFTs and in IOS before and after the vaping of the EC in both groups.
There were no significant correlations between the changes in FeNO and the changes in respiratory mechanics before and after EC in the control group (Table 1). On the other hand, the difference in FeNO before and after EC in the asthmatics was significantly correlated with the corresponding differences in residual volume (RV), total lung capacity and respiratory impedance at 5 Hz (Z5Hz) (Table 1). Furthermore, the difference in FeNO before and after EC in the asthmatics was correlated with the corresponding differences in respiratory resistance at 5 and 20 Hz (R5Hz and R20Hz) at the limit of significance, where the number 0.000 was the lowest limit of the 95% of the confidence intervals (Table 1). However no significant correlations were found between the changes in the EBC biomarkers and the changes in respiratory mechanics before and after EC neither in the asthmatic nor in the control group.
Conrol group (n = 25) | |||
Variable | Unstandardized coefficients (B) (95%CI) | Standardised coefficients (r) | P value |
diff_FEV1 (L) | 0.004 (-0.009–0.016) | 0.131 | 0.53 |
diff_FVC (L) | -0.004 (-0.021–0.014) | -0.089 | 0.67 |
diff_FEV1/FVC (%) | 0.096 (-0.216–0.407) | 0.131 | 0.53 |
diff_PEF (L/s) | -0.065 (-0.166–0.035) | -0.269 | 0.19 |
diff_FEF25-75 (L/s) | 0.000 (-0.053–0.054) | 0.004 | 0.99 |
diff_RV (L) | 0.010 (-0.005–0.025) | 0.281 | 0.17 |
diff_TLC (L) | 0.001 (-0.018–0.019) | 0.015 | 0.94 |
diff_Z5Hz (kPa/L/s) | 0.000 (-0.006–0.006) | -0.012 | 0.96 |
diff_R5Hz (kPa/L/s) | -0.001 (-0.007–0.004) | -0.112 | 0.59 |
diff_R20Hz (kPa/L/s) | -0.001 (-0.006–0.000) | -0.044 | 0.84 |
Asthma group (N = 25) | |||
diff_FEV1 (L) | -0.007 (-0.016–0.002) | -0.327 | 0.11 |
diff_FVC (L) | 0.005 (-0.005–0.015) | 0.203 | 0.33 |
diff_FEV1/FVC (%) | -0.027 (-0.173–0.119) | -0.080 | 0.71 |
diff_PEF (L/sec) | -0.010 (-0.087–0.066) | -0.059 | 0.78 |
diff_FEF25-75 (L/s) | -0.007 (-0.033–0.020) | -0.110 | 0.60 |
diff_RV (L) | 0.027 (0.005–0.049) | 0.465 | 0.019 |
diff_TLC (L) | 0.018 (0.005–0.031) | 0.519 | 0.008 |
diff_Z5Hz (kPa/L/s) | 0.005 (0.000–0.010) | 0.402 | 0.046 |
diff_R5Hz (kPa/L/s) | 0.005 (0.000–0.010) | 0.386 | 0.057 |
diff_R20Hz (kPa/L/s) | 0.003 (0.000–0.006) | 0.358 | 0.078 |
FeNO has been associated with Th2 regulated asthma, reflecting eosinophilic inflammation[14]. Z5Hz is increased in worsening asthma[4,5], and the same applies for both R20Hz and R5Hz which reflect large and total airway resistance respectively[4,5]. The association between the changes in FeNO and in Z5Hz, R5Hz and R20Hz in the asthmatics after vaping could be attributed to the aggravation of airway inflammation in these patients (increase of FeNO), leading to bronchoconstriction (increase in impulse oscillometry indices), something that was not the case for the control group.
The increase of RV and TLC indicates the existence of air trapping and hyperinflation in obstructive lung diseases[15,16]. The correlation between the difference in FeNO before and after EC and the corresponding differences in RV and TLC in the asthmatic patients means that the deterioration of the airway inflammation is significantly associated with air trapping and hyperinflation, something not observed in the control group. This is particularly interesting since these defects are not as common in asthma as in COPD and when they are observed in asthma, they are associated with longer disease duration and fixed airflow obstruction[17,18].
The main limitation of this study is the relatively small number of participants in each group. Perhaps, this is the reason why the correlation between the difference in FeNO and the difference in R5Hz and R20Hz were at the limit of significance and there was no statistically significant correlation between the difference in FeNO and the differences in other key asthma indices such as forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC, peak expiratory flow and forced expiratory flow between 25% and 75% of FVC (FEF25-75). Possibly for the same reason there were no significant correlations between the changes in the EBC biomarkers and the changes in respiratory mechanics. Additional limitations of the study are that the measurements during the follow up were assessed only in one timepoint after EC, and only a specific brand of EC was used. Asthma is a chronic inflammatory airway disease that requires a long period of time for treatment and evaluation. Evaluating only the changes in lung function related indices or markers after a single inhalation of EC might not illustrate the effect of EC on asthma lung function. Additionally, only well controlled asthmatic patients of GINA “step-3” were evaluated. All the asthmatic patients studied were receiving treatment with inhaled corticosteroids (ICS) and it is possible that the presence of ICS could have implicated with the changes in lung function and airway inflammation[19,20], after the use of the EC.
In conclusion, this study demonstrates that there is a direct association between airway inflammation and respiratory mechanics in patients with asthma after the use of EC, even in patients receiving ICS. As EC becomes more popular, there is an urgent need for studies which will assess its effects in human health, especially in certain group of respiratory patients as those with asthma.
Electronic cigarette (EC) is a novel smoking product promoted to replace tobacco cigarette in smokers' daily habits. However, despite the fact that the effects of the tobacco cigarette have been investigated thoroughly the last decades, this is not the case for EC. There is evidence that EC have several acute effects on lung function of healthy individuals, and on lung function and airway inflammation of patients with asthma and chronic obstructive pulmonary disease. In a previous study, we have evaluated the acute effects of EC on lung function and airway inflammation in patients with asthma compared to healthy individuals. However, we did not evaluate the possible correlations of the changes on airway inflammation with the acute effects of EC on lung function.
With this study we investigate the correlations between the changes in airway inflammation, reflected by the changes in fraction exhaled Nitric Oxide (FeNO) and exhaled breathe condensate (EBC) biomarkers, with the changes in pulmonary function tests (PFTs) and impulse oscillometry after vaping one nicotine-containing EC.
With this study we investigate the correlations between the changes in airway inflammation, reflected by the changes in FeNO and EBC biomarkers, with the changes in PFTs and impulse oscillometry after vaping one nicotine-containing EC.
The protocol of this study was approved by the Ethics Committee of the Medical School, Aristotle University of Thessaloniki, reference 369-8/22.2.2017, before the initiation of enrolment and all participants gave their written informed consent. The protocol of the study was also registered in ISRCTN-registry (ISRCTN89151172).
There were no significant correlations between the changes in FeNO and the changes in respiratory mechanics before and after EC in the control group. On the other hand, the difference in FeNO before and after EC in the asthmatics was significantly correlated with the corresponding differences in residual volume, total lung capacity and respiratory impedance at 5 Hz. Furthermore, the difference in FeNO before and after EC in the asthmatics was correlated with the corresponding differences in respiratory resistance at 5 and 20 Hz (R5Hz and R20Hz) at the limit of significance, where the number 0.000 was the lowest limit of the 95% of the confidence intervals. However no significant correlations were found between the changes in the EBC biomarkers and the changes in respiratory mechanics before and after EC neither in the asthmatic nor in the control group.
In conclusion, this study demonstrates that there is a direct association between airway inflammation and respiratory mechanics in patients with asthma after the use of EC, even in patients receiving inhaled corticosteroids.
As EC becomes more popular, there is an urgent need for studies which will assess its effects in human health, especially in certain group of respiratory patients as those with asthma.
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Medicine, research and experimental
Country/Territory of origin: Greece
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): D
Grade E (Poor): 0
P-Reviewer: Meng FZ, China S-Editor: Liu JH L-Editor: A P-Editor: Yu HG
1. | Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou V, Connolly GN, Behrakis PK. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest. 2012;141:1400-1406. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 354] [Cited by in F6Publishing: 366] [Article Influence: 28.2] [Reference Citation Analysis (0)] |
2. | Staudt MR, Salit J, Kaner RJ, Hollmann C, Crystal RG. Altered lung biology of healthy never smokers following acute inhalation of E-cigarettes. Respir Res. 2018;19:78. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 76] [Cited by in F6Publishing: 89] [Article Influence: 14.8] [Reference Citation Analysis (0)] |
3. | Reinikovaite V, Rodriguez IE, Karoor V, Rau A, Trinh BB, Deleyiannis FW, Taraseviciene-Stewart L. The effects of electronic cigarette vapour on the lung: direct comparison to tobacco smoke. Eur Respir J. 2018;51. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis (0)] |
4. | Kotoulas SC, Pataka A, Domvri K, Spyratos D, Katsaounou P, Porpodis K, Fouka E, Markopoulou A, Passa-Fekete K, Grigoriou I, Kontakiotis T, Argyropoulou P, Papakosta D. Acute effects of e-cigarette vaping on pulmonary function and airway inflammation in healthy individuals and in patients with asthma. Respirology. 2020;25:1037-1045. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis (0)] |
5. | Lappas AS, Tzortzi AS, Konstantinidi EM, Teloniatis SI, Tzavara CK, Gennimata SA, Koulouris NG, Behrakis PK. Short-term respiratory effects of e-cigarettes in healthy individuals and smokers with asthma. Respirology. 2018;23:291-297. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis (0)] |
6. | Palamidas A, Tsikrika S, Katsaounou PA, Vakali S, Gennimata SA, Kaltsakas G, Gratziou C, Koulouris N. Acute effects of short term use of ecigarettes on Airways Physiology and Respiratory Symptoms in Smokers with and without Airway Obstructive Diseases and in Healthy non smokers. Tob Prev Cessat. 2017;3:5. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis (0)] |
7. | Higham A, Bostock D, Booth G, Dungwa JV, Singh D. The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses. Int J Chron Obstruct Pulmon Dis. 2018;13:989-1000. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 41] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis (0)] |
8. | "Global strategy for asthma management and prevention: GINA executive summary." E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, J.M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S.E. Pedersen, E. Pizzichini, S.D. Sullivan, S.E. Wenzel and H.J. Zar. Eur Respir J 2008; 31: 143-178. Eur Respir J. 2018;51. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
9. | CDC. National Health Interview Survey (2017) Adult Tobacco Use Information. CDC/National Center for Health Statistics. Accessed: July 2, 2021. Available from: https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm. [Cited in This Article: ] |
10. | Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319-338. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9568] [Cited by in F6Publishing: 11004] [Article Influence: 611.3] [Reference Citation Analysis (0)] |
11. | Oostveen E, MacLeod D, Lorino H, Farré R, Hantos Z, Desager K, Marchal F; ERS Task Force on Respiratory Impedance Measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22:1026-1041. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 769] [Cited by in F6Publishing: 806] [Article Influence: 40.3] [Reference Citation Analysis (0)] |
12. | American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912-930. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2365] [Cited by in F6Publishing: 2502] [Article Influence: 131.7] [Reference Citation Analysis (0)] |
13. | Horváth I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jöbsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26:523-548. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 864] [Cited by in F6Publishing: 859] [Article Influence: 45.2] [Reference Citation Analysis (0)] |
14. | Riise GC, Torén K, Olin AC. Subjects in a Population Study with High Levels of FENO Have Associated Eosinophil Airway Inflammation. ISRN Allergy. 2011;2011:792613. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
15. | Vaz Fragoso CA, Cain HC, Casaburi R, Lee PJ, Iannone L, Leo-Summers LS, Van Ness PH. Spirometry, Static Lung Volumes, and Diffusing Capacity. Respir Care. 2017;62:1137-1147. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
16. | Alter P, Orszag J, Kellerer C, Kahnert K, Speicher T, Watz H, Bals R, Welte T, Vogelmeier CF, Jörres RA. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Res. 2020;6. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
17. | Tiwari A, Rahman K, Abejie B, Jain VV, Vempilly JJ. Longer duration of asthma is significantly associated with increased RV/TLC ratio. Respir Med. 2017;124:44-48. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis (0)] |
18. | Pornsuriyasak P, Khiawwan S, Rattanasiri S, Unwanatham N, Petnak T. Prevalence of small airways dysfunction in asthma with- and without-fixed airflow obstruction and chronic obstructive pulmonary disease. Asian Pac J Allergy Immunol. 2021;39:296-303. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis (0)] |
19. | Kharitonov SA, Barnes PJ. Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:191-199. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
20. | Konstantinidi EM, Lappas AS, Tzortzi AS, Behrakis PK. Exhaled Breath Condensate: Technical and Diagnostic Aspects. ScientificWorldJournal. 2015;2015:435160. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 9.3] [Reference Citation Analysis (0)] |